<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599765</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0349</org_study_id>
    <secondary_id>NCI-2018-01469</secondary_id>
    <secondary_id>2018-0349</secondary_id>
    <nct_id>NCT03599765</nct_id>
  </id_info>
  <brief_title>Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor</brief_title>
  <official_title>External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well systemic therapy with or without local consolidative&#xD;
      therapy work in treating patients with solid tumor that has spread to 1 site of other places&#xD;
      in the body. Treatment with up-front local consolidative therapy may be better in helping to&#xD;
      control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. In patients with oligometastatic malignancies, to assess progression free survival (PFS)&#xD;
      with upfront local consolidative therapy (LCT) versus (vs.) no LCT among randomized patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. In patients with oligometastatic malignancies, to assess overall survival (OS) with&#xD;
      upfront LCT vs. no LCT among randomized patients.&#xD;
&#xD;
      II. In patients with oligometastatic malignancies, to assess time to next line systemic&#xD;
      therapy with upfront LCT vs. no LCT.&#xD;
&#xD;
      III. In patients with oligometastatic malignancies, to assess time to new lesion failure with&#xD;
      upfront LCT vs. no LCT.&#xD;
&#xD;
      IV. To assess safety/tolerability of upfront LCT in patients with oligometastatic&#xD;
      malignancies.&#xD;
&#xD;
      V. In patients with oligometastatic malignancies, to assess quality of life with upfront LCT&#xD;
      vs. no LCT.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To identify predictive/prognostic biomarkers that are associated with a benefit to LCT&#xD;
      across disease sites.&#xD;
&#xD;
      II. To investigate the systemic immune activating effects of radiation.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive up-front standard of care LCT including but not limited to surgical&#xD;
      resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug&#xD;
      therapy.&#xD;
&#xD;
      ARM II: Patients receive routine drug therapy. Patients may later receive LCT at the&#xD;
      discretion of doctor.&#xD;
&#xD;
      After completion of study, patients are followed up every 18 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>General descriptive statistics will be computed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to development of new distant metastases</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">367</enrollment>
  <condition>Oligometastatic Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (LCT, routine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (routine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive routine therapy</description>
    <arm_group_label>Arm I (LCT, routine therapy)</arm_group_label>
    <arm_group_label>Arm II (routine therapy)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local Consolidation Therapy</intervention_name>
    <description>Receive LCT</description>
    <arm_group_label>Arm I (LCT, routine therapy)</arm_group_label>
    <other_name>LCT</other_name>
    <other_name>Local Consolidative Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oligometastatic solid tumors (see protocol for relevant disease sites) patients (=&lt; 5&#xD;
             metastatic lesions at the time of study entry)&#xD;
&#xD;
          -  Candidate for definitive local therapy to all sites of active disease per the&#xD;
             discretion of the treating physicians&#xD;
&#xD;
          -  No more than 4 prior lines of systemic therapy administered to treat metastatic&#xD;
             disease&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of cancer as specified in protocol&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 500/mcL (performed within 6 weeks prior to study&#xD;
             enrollment)&#xD;
&#xD;
          -  Platelets &gt;= 25,000/mcL (performed within 6 weeks prior to study enrollment)&#xD;
&#xD;
          -  Hemoglobin &gt;=7 g/dL (performed within 6 weeks prior to study enrollment)&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 mg/dl (except for subjects with Gilbert syndrome, who may&#xD;
             have total bilirubin &lt; 3.0 mg/dl) OR direct bilirubin =&lt; upper limit normal (ULN) for&#xD;
             subjects with total bilirubin levels &gt; 1.5 mg/dl (performed within 6 weeks prior to&#xD;
             study enrollment)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and&#xD;
             alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =&lt; 3 X ULN&#xD;
             OR =&lt; 5 X ULN for subjects with liver metastases (performed within 6 weeks prior to&#xD;
             study enrollment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in&#xD;
             the opinion of the treating radiation oncologist precludes safe radiation therapy&#xD;
&#xD;
          -  Metastatic effusion (e.g. pleural effusion or ascites). Note that patients with an&#xD;
             effusion that is too small to sample will be eligible for the trial&#xD;
&#xD;
          -  Diffuse metastatic processes including leptomeningeal disease, diffuse bone marrow&#xD;
             involvement, and peritoneal carcinomatous, which by the discretion of the treating&#xD;
             physician cannot be treated definitively&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          -  In the event that a curative systemic option exists for metastatic disease from a&#xD;
             given disease site. First-line metastatic patients (those patients who have had no&#xD;
             prior lines of systemic therapy targeting their metastatic disease) are only eligible&#xD;
             for enrollment if they have completed their curative systemic therapy per the judgment&#xD;
             of the treating oncologist and have persistent disease&#xD;
&#xD;
          -  Is pregnant or expecting to conceive within the projected duration of the trial at the&#xD;
             screening visit&#xD;
&#xD;
               -  Female subject of childbearing potential should have a negative urine or serum&#xD;
                  pregnancy within 6 weeks prior to study registration up to the first fraction of&#xD;
                  radiation&#xD;
&#xD;
               -  Note: If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
                  pregnancy test will be required&#xD;
&#xD;
          -  Additional diagnosis of another primary malignancy outside of the malignancy being&#xD;
             treated on trial that per the discretion of the treating physicians and&#xD;
             investigational team offers a substantial risk to the patient's life (e.g. primary&#xD;
             lung cancer definitively treated in the past 6 months would offer a significant risk&#xD;
             to the patient's life, while a basal cell carcinoma treated with local excision would&#xD;
             not)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Tang</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chad Tang</last_name>
    <phone>713-563-2300</phone>
    <email>ctang1@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lewis and Faye Manderson Cancer Center</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James C. Tucker</last_name>
      <email>jctucker@oawa.net</email>
    </contact>
    <investigator>
      <last_name>James C. Tucker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary V. Walker</last_name>
      <email>gary.walker@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Gary V. Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael R. Olson</last_name>
      <email>Michael.olson@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Michael R. Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stuart Y. Tsuji</last_name>
      <email>stsuji@queens.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Y. Tsuji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Health Center</name>
      <address>
        <city>Coldwater</city>
        <state>Michigan</state>
        <zip>49036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel W. Weed</last_name>
      <email>dweed@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Daniel W. Weed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan A. Mezera</last_name>
      <email>mezera-megan@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Megan A. Mezera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OhioHealth Mansfield Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew B. Freeman</last_name>
      <email>andrew.freeman@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew B. Freeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Tang</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Chad Tang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen G. Chun</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Stephen G. Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen G. Chun</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Stephen G. Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad H. Fakhreddine</last_name>
      <phone>210-450-5652</phone>
      <email>fakhreddine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamad H. Fakhreddine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen G. Chun</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Stephen G. Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen G. Chun</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Stephen G. Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

